775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study-Reference-Cited by-同舟云学术

775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

Published:2021-08 Issue:2 Volume:161 Page:e30-e31
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Sands Bruce E.,Irving Peter M.,Hoops Timothy,Izanec James L.,Gao Long-Long,Gasink Christopher,Greenspan Andrew,Allez Matthieu,Danese Silvio,Hanauer Stephen B.,Jairath Vipul,Kuehbacher Tanja,Lewis James D.,Loftus Edward V.,Mihaly Emese,Panaccione Remo,Scherl Ellen J.,Shchukina Oksana,Sandborn William J.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study;Therapeutic Advances in Gastroenterology;2024-01

2. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY;Inflammatory Bowel Diseases;2023-10-31

3. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab;Current Medical Research and Opinion;2023-08-26

4. Author's Reply: ``Use of biologics for the management of Crohn's disease'';Digestive and Liver Disease;2023-07

5. The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease;International Journal of Molecular Sciences;2023-06-15